Peptonic Medical publishes an Information Memorandum

Stockholm, November 25, 2015. Peptonic Medical AB (publ) (”Peptonic Medical” or the ”Company”)  – a company developing pharmaceuticals based on oxytocin – today announces that the Information Memorandum regarding the Company’s rights issue (the ”Offer”) is now available on the Company’s website www.peptonicmedical.se

• The Board of Peptonic Medical today publishes an Information Memorandum with regards to the Offer of approximately MSEK 22.7
• Detailed information regarding the Offer is available on www.peptonicmedical.se, www.partnerfk.se and www.aktietorget.se
• The subscription period is between November 27, 2015, and December 11, 2015
• Trading in subscription rights will take place between November 27, 2015, and December 9, 2015

For further information, please contact:

Johan Inborr, CEO
Phone: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se

About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)’s mission is to develop safe and effective drugs based on oxytocin.